Kneat.com (KSI) Small-Cap Growth Virtual Investor Conference 2024 summary

Business overview and market position

• Provides a SaaS platform for quality management and validation in life sciences, addressing critical compliance and data integrity needs.

• Achieved 138% net revenue retention at the end of 2023, driven by a land and expand model with large pharmaceutical and medical device customers.

• Platform is widely adopted, with some customers scaling to 10,000 users across 27 global sites.

• Most of the top 20 global pharmaceutical companies are customers, demonstrating significant market penetration.

• Focuses on mission-critical processes, ensuring regulatory compliance and audit readiness for clients.

Product features and customer value

• Eliminates paper-based processes, enabling digital validation and instant access to audit data.

• Configurable platform supports multiple validation use cases without coding, allowing rapid deployment and expansion.

• Real-time compliance monitoring and centralized data access de-risk business operations.

• Platform supports a wide range of validation needs, including equipment, process, computer systems, and cold chain validation.

• Customers report 50% savings in man-hours and cycle time, with improved right-first-time compliance and faster time to market.

Market opportunity and growth strategy

• Core addressable market in life sciences validation estimated at $2 billion ARR, with potential to expand to $7 billion by addressing adjacent needs.

• Further expansion into broader quality, manufacturing, and knowledge management could increase TAM to over $15 billion.

• Growth is primarily organic, with a focus on integration and platform expansion based on customer demand.

• No current plans for acquisitions; emphasis remains on organic growth and platform development.

• Positioned to benefit from increasing automation demand among regulated companies.